Enhancement of Leishmania amazonensis infection in BCG non-responder mice by BCG-antigen specific vaccine

• Main Authors: Kátia da Silva Calabrese, Sylvio Celso Gonçalves da Costa
• Format: Article
• Language: English
• Published: Instituto Oswaldo Cruz, Ministério da Saúde 1992-01-01
• Series: Memórias do Instituto Oswaldo Cruz.
• Subjects: Leishmania amazonensis; inbred mice; vaccination; BCG; microsomal fraction
• Online Access: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761992000500010
• ISSN: 0074-0276; 1678-8060

Different patterns of cutaneous leishmaniasis can be induced when a challenge of alike dose of Leishmania amazonensis amastigotes in various inbred strains was applied. Two strains of mice, the Balb/c and C57 BL/10J, showed exceptional suscepbility, and 10(elevado a sexta potência) amastigotes infective dose lead, to ulcerative progressive lesions with cutaneous metastasis and loss by necrosis of leg on wich the footpad primary lesion occured. Lesions were also progressive but in a lower degree when C3H/HeN and C57BL/6 were infected. Lesions progress slowly in DBA/2 mice presenting lesions wich reach a discreet peack after 12 weeks, do not heal but do not uncerate. DBA/2 mice is, therefore, a good model for immunomodualtion. In attempt to determine the influence of BCG in vaccination schedule using microsomal fraction, DBA/2 became an excellent model, since it is also a non-responder to BCG. Vaccination of DBA/2 mice, receiving the same 10(elevado a sexta potência) BCG viable dose and 10 *g or 50 *g of protein content of microsomal fraction, lead to a progressive disease with time course similar to those observed in susceptible non-vaccinated C57BL/10J mice after 6 months of observation. An enhancement of infection in BCG non-responder mice suggests that use of BCG as immunostimulant in humans could be critical for both vaccination and immunoprophylactic strategies.